3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Sleep Initiation and Maintenance Disorders
30
Neoplasms
21
Breast Neoplasms
19
Depression
12
Anxiety Disorders
12
Prostatic Neoplasms
8
Fatigue
8
Lung Neoplasms
5
Motor Activity
4
Lymphoma
4
Weight Loss
3
Uterine Cervical Neoplasms
3
Melanoma
3
Chronic Pain
3
Smoking Cessation
2
Sleep Wake Disorders
2
Pain
2
Overweight
2
Ovarian Neoplasms
2
Obesity
2
Nervous System Diseases
2
Multiple Myeloma
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Cognitive Dysfunction
2
Carcinoma, Non-Small-Cell Lung
2
Weight Gain
1
Uterine Neoplasms
1
Tobacco Use Disorder
1
Interventions
rozanolixizumab
10
zilucoplan
8
efgartigimod alfa
8
Rituximab
7
Cyclophosphamide
7
telitacicept
6
fludarabine
6
eculizumab
5
Prednisone
5
ravulizumab
4
Pyridostigmine Bromide
4
Immunoglobulins, Intravenous
4
Hizentra
4
Tacrolimus
3
Mycophenolic Acid
3
HBM9161
3
Amifampridine
3
thymoglobulin
2
inebilizumab
2
Prednisolone
2
Exercise
2
tofacitinib
1
tocilizumab
1
talquetamab
1
satralizumab
1
sargramostim
1
rhoA GTP-Binding Protein
1
remibrutinib
1
prednylidene
1
iscalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Myasthenia Gravis
×
Cognitive Behavioral Therapy
×
Clear all
NCT06659627
2025-09-09
FIT to ACT-MG
Leiden University Medical Center
Phase NA
Recruiting
60 enrolled